The effect of smoking on the course of the disease and lipid metabolism in patients with community-acquired pneumonia
Abstract
Introduction. Community-acquired pneumonia (CAP) is a disease associated with a high risk of complications and mortality, which depends on various risk factors. Smoking is one such factor that contributes to an unfavorable prognosis in various conditions. Objectives. This study aimed to assess the impact of smoking status on the course of CAP and to explore the relationship between smoking, pneumonia severity, and lipid metabolism. A total of 255 patients with CAP were included and divided into two groups: those with moderately severe pneumonia (119 patients) and those with severe pneumonia (136 patients). Among the examined patients, men predominated, and the vast majority were young. The most common complications included pleurisy, myocarditis, and renal dysfunction. Results. The incidence of complications and severe clinical course of CAP was similar in smokers and non-smokers. However, decreased body mass index (BMI) was slightly more common in smokers. Notably, low body mass was twice as frequent among smokers with severe pneumonia compared to non-smokers with severe disease. Systolic and diastolic blood pressure values were significantly lower in smokers. The number of peripheral blood leukocytes was significantly higher in smokers. C-reactive protein (CRP) levels were elevated in both groups. While the average fibrinogen levels did not differ significantly between groups, hyperfibrinogenemia (>10 g/L) was more common in smokers with severe pneumonia. Cholesterol…
Read the paper
Related studies
- Tobacco and COPD: presenting the World Health Organization (WHO) Tobacco Knowledge Summary
- Comparative effects of e-cigarette smoking on periodontal status, salivary pH, and cotinine levels
- Association between exposure to environmental pollutants and increased oral health risks, a comprehensive review
- Influence of gestational window on offspring vascular health in rodents with in utero exposure to electronic cigarettes
- Natural products as kinase inhibitors in lung cancer: molecular mechanisms, therapeutic potential, and clinical trials
- Nicotine in electronic cigarettes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.